The tumor suppressor p53 (TP53) is mutated in ~70 % of colorectal cancer (CRC) cases. Of these cases, approximately 80 % undergo subsequent p53 loss-of-heterozygosity (p53LOH), losing the remaining wildtype p53 (WTp53) ...